At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CLDX Celldex Therapeutics
Trading 11-05 11:40:01 EST
25.19
-0.20
-0.78%
High25.69
Low24.88
Vol232.87K
Open25.34
D1 Closing25.39
Amplitude3.21%
Mkt Cap1.67B
Tradable Cap1.67B
Total Shares66.29M
T/O5.89M
T/O Rate0.35%
Tradable Shares66.10M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
BRIEF-Celldex Announces Barzolvolimab Met All Primary And Secondary Endpoints With High Statistical Significance In Positive Phase 2 Study In Chronic Inducible Urticaria
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints With High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
BRIEF-Celldex Announces Upcoming Late Breaking Oral Presentation Of 12 Week Results From Barzolvolimab Phase 2 Study In Chronic Inducible Urticaria At Acaai 2024
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results From Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at Acaai 2024
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.